Meet the ophthalmology-focused pharmaceutical company trying to raise $86M

Eric Oliver - Print  |

Tarsus Pharmaceuticals is attempting to raise $86 million through an initial public offering, Nasdaq reports.

Tarsus is a late-stage biopharmaceutical company focused on developing therapies for ophthalmology conditions.

Tarsus' lead pipeline candidate, TP-03, is attempting to treat Demodex blepharitis. This treatment has completed four phase 2 trials to date. It expects to launch a phase 2b/3 trial in September.

Tarsus was founded in 2016.

More articles on surgery centers:
12-OR ASC part of $295M Florida orthopedic hospital expansion
3 ASCs launching total joint programs
4 ASCs installing total joint robots

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.